PROSTATIC MESENCHYMAL TUMOR IN YOUNG ADULT: A CASE REPORT
Abstract
Neoplasm in the mesenchymal tissue is only about 0.1% of the total tumors that occur in the prostate and potent to be malignant. Prostate stromal sarcoma (PSS) mostly have poor prognosis, about 50% will die within 2 years or even shorter. Here, we report a 46-years old male presented with LUTS and progressed to be urinary retention in 2 weeks. The examination results did not suggest malignancy. Digital rectal examination (DRE) showed an enlarged prostate with soft consistency and regular surface. Transabdominal ultrasonography examination showed homogeneous prostate echostructure with a volume of 80ml3, and total prostate spesific antigen (PSA) is 0.57 ng/mL. The patient then underwent transurethral resection of postate (TURP), apparently the histopathologic interpretation showed a prostate mesenchymal tumor. These tumors are divided into Stromal Tumor of Uncertain Malignant Potential (STUMP) and PSS, which should be common in 7th decade. The patient was found to have a mesenchymal tumor incidentally from prostate resection tissue. After that, an abdominal CT-Scan with contrast was performed to determine the possibility of metastasis. The patient was adviced to monitor the growth and spread of the tumor. Mesenchymal tumors are still a rare case, because the small number of similar cases reported due to very small tissues size, difficulty in distinguishing stromal neoplasms, and limited expertise of pathologists in interpreting, so we need more cases series to consider the standard therapy.
Downloads
References
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules. 2022 Sep 5;27(17):5730.
International Agency for Research on Cancer, World Health Organization. Cancer Today: Estimated number of new cases in 2020, World, males, all ages. World Health Organization [Internet]. 2021 Mar; Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1
Mottet N, Cornford P, Van den bergh RCN, Briers E, De Santis M, Gillessen S, et al. PROSTATE CANCER. In: European Association of Urology Guidelines. European Association of Urology; 2022. (2022).
Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, Campbell MF, Walsh PC, et al., editors. Campbell-Walsh-Wein Urology. Volume 3: in Campbell-Walsh-Wein Urology. Partin, A.W., ed. Dmochowski, R.R., Kavoussi, L.R., Peters, C.A. Twelfth edition. Philadelphia, PA: Elsevier; 2021. 2345 p.
McKenney JK. Mesenchymal tumors of the prostate. Mod Pathol. 2018 Jan;31:133–42.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19.
De Berardinis E, Busetto GM, Antonini G, Giovannone R, Di Placido M, Maglioccia FM, et al. Incidental Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP): Histopathological and Immunohistochemical Findings. Urol J. 2012 Jan;79(1):65–8.
Marcal LP, Surabhi VR, Ramani NS, Katabathina VS, Paspulati RM, Prasad SR. Mesenchymal Neoplasms of the Prostate and Seminal Vesicles: Spectrum of Disease with Radiologic-Pathologic Correlation. Radiographics. 2022 Mar;42(2):417–32.
Kass-Illiya A, Karavaggelis A, Koupparis A. Prostatic Stromal Tumour of Uncertain Malignant Potential (STUMP): A Case Presentation and Literature Review. J Urol Forecast. 2018 Feb 13;1(1):1002.
Roos FC, Sommer S, Hampel C, Melchior SW, Thüroff JW. Extraprostatic Spindle Cell Stromal Tumor of the Prostate: Case Report. Urology. 2008 Jun;71(6):1226.e13-1226.e15.
Copyright (c) 2024 Medika Alkhairaat: Jurnal Penelitian Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan agree to the following terms:
1. Authors retain copyright and grant Journal Medika Alkhairaat right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgement of the work’s authorship and initial publication in Journal Medika Alkhairaat.
2. Authors are permitted to copy and redistribute the journal’s published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Journal Medika Alkhairaat.
